University Library
  • Login
A gateway to Melbourne's research publications
Minerva Access is the University's Institutional Repository. It aims to collect, preserve, and showcase the intellectual output of staff and students of the University of Melbourne for a global audience.
View Item 
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Centre for Cancer Research
  • Centre for Cancer Research - Research Publications
  • View Item
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Centre for Cancer Research
  • Centre for Cancer Research - Research Publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

    Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study.

    Thumbnail
    Download
    Published version (216.7Kb)

    Citations
    Scopus
    Altmetric
    7
    Author
    Spencer, A; Roberts, A; Kennedy, N; Ravera, C; Cremers, S; Bilic, S; Neeman, T; Copeman, M; Schran, H; Lynch, K
    Date
    2008-03-31
    Source Title
    BMC Clinical Pharmacology
    Publisher
    Springer Science and Business Media LLC
    University of Melbourne Author/s
    Roberts, Andrew
    Affiliation
    Centre for Cancer Research
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Spencer, A., Roberts, A., Kennedy, N., Ravera, C., Cremers, S., Bilic, S., Neeman, T., Copeman, M., Schran, H. & Lynch, K. (2008). Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study.. BMC Clin Pharmacol, 8 (1), pp.2-. https://doi.org/10.1186/1472-6904-8-2.
    Access Status
    Open Access
    URI
    http://hdl.handle.net/11343/254945
    DOI
    10.1186/1472-6904-8-2
    Open Access at PMC
    http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2330021
    Abstract
    BACKGROUND: Cases of impaired renal function have been reported in patients who had been treated with both zoledronic acid and thalidomide for myeloma. Hence, we conducted a safety study of zoledronic acid and thalidomide in myeloma patients participating in a trial of maintenance therapy. METHODS: Twenty-four patients who were enrolled in a large randomized trial of thalidomide vs no thalidomide maintenance therapy for myeloma, in which all patients also received zoledronic acid, were recruited to a pharmacokinetic and renal safety sub-study, and followed for up to 16 months. RESULTS: No significant differences by Wilcoxon rank-sum statistic were found in zoledronic acid pharmacokinetics or renal safety for up to 16 months in patients randomized to thalidomide or not. CONCLUSION: In myeloma patients receiving maintenance therapy, the combination of zoledronic acid and thalidomide appears to confer no additional renal safety risks over zoledronic acid alone.

    Export Reference in RIS Format     

    Endnote

    • Click on "Export Reference in RIS Format" and choose "open with... Endnote".

    Refworks

    • Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References


    Collections
    • Minerva Elements Records [52443]
    • Centre for Cancer Research - Research Publications [83]
    Minerva AccessDepositing Your Work (for University of Melbourne Staff and Students)NewsFAQs

    BrowseCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    My AccountLoginRegister
    StatisticsMost Popular ItemsStatistics by CountryMost Popular Authors